CRISPR Therapeutics stock (CH0334081137): Bernstein raises price target amid gene-editing momentum

Bernstein maintained its rating on CRISPR Therapeutics while raising the price target to $56, signaling confidence in the gene-editing platform developer's therapeutic pipeline.

CRISPR Therapeutics, the Swiss-based biopharmaceutical company pioneering CRISPR/Cas9 gene-editing therapies, has attracted fresh analyst attention as Bernstein raised its price target on the stock, according to recent market coverage. The stock traded at $52.75 USD on May 14, 2026, on Nasdaq, reflecting modest volatility in the biotech sector.

As of: May 14, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: CRISPR Therapeutics AG
• Sector/industry: Biotechnology, gene editing
• Headquarters/country: Switzerland
• Core markets: United States, Europe
• Key revenue drivers: CRISPR/Cas9-based therapeutic development and licensing
• Home exchange/listing venue: Nasdaq (CRSP)
• Trading currency: USD
• Market capitalization: Approximately $5.09 billion

CRISPR Therapeutics: core business model

CRISPR Therapeutics AG specializes in the development of gene-editing therapies based on the CRISPR/Cas9 platform, a revolutionary molecular tool that allows precise editing of DNA sequences. Founded in 2013, the company operates as a clinical-stage biopharmaceutical enterprise with a focus on treating genetic diseases and certain cancers. The company's platform represents one of the most advanced gene-editing approaches in clinical development, positioning it as a key player in the emerging precision medicine landscape that US investors increasingly monitor for long-term growth potential.

Main revenue and product drivers for CRISPR Therapeutics

The company's pipeline centers on CRISPR/Cas9-based therapeutics designed to address unmet medical needs in oncology, hematology, and genetic disorders. Revenue generation remains limited at the clinical-stage phase, with the company primarily funded through capital raises and potential milestone payments from partnerships. As the gene-editing sector matures, CRISPR Therapeutics' ability to advance candidates through regulatory approval and achieve commercialization will determine its financial trajectory and investor returns.

Conclusion

CRISPR Therapeutics remains a focal point for investors tracking gene-editing innovation and precision medicine development. The Bernstein price target adjustment reflects ongoing confidence in the company's therapeutic platform, though clinical-stage biotech companies carry inherent execution risks. US investors should monitor regulatory milestones, clinical trial outcomes, and partnership developments as key catalysts for the stock's performance trajectory.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.